CDKN2A and neoplasm: To estimate which percentage of osteosarcoma patients might be eligible for palbociclib treatment, the expression levels of proteins in the p16-Rb pathway, including Rb, CDK4, CDK6 and p16, was determined in primary tumour tissue of 109 patients using TMA (Table 1; Fig. 6A).